Derick Gabel

Clinical Cardiology Pharmacist at OHSU. PGY1&2 Acute Care and Cardiology at WakeMed Health & Hospitals. PharmD at Campbell University.

[Derick Gabel @derick_gabel]

@DGlaucomflecken Interns are great. They are open minded, want to learn, and are very accessible. They are also the ones pharmacy gets a million questions from in July/August😂

Kidding aside, I get so much joy teaching, answering questions, and helping the interns advance their practice.

[Derick Gabel @derick_gabel]

@DGlaucomflecken Same thing in pharmacy. Although my yearly fees to maintain BCPS/BCCP are a lot cheaper, so I guess it’s ok…

[Ryan Caputo, PharmD, BCCP @RyanCaputo1]

Spironolactone doesn’t get the love it deserves 😢

[Dr. Glaucomflecken @DGlaucomflecken]

The July effect

[European Society of Cardiology Journals @ESC_Journals]

Emerging role for #SGLT2 inhibitors in mitigating the risk of hyperkalaemia in heart failure https://t.co/P6uWoAcmdi

@ehj_ed @rladeiraslopes #EHJ #ESCYoung

[ACCP Cardiology PRN @accpcardprn]

#TeachingTuesday IS BACK! Please join the ACCP Cardiology PRN starting Tuesday, Feb 1st for our very first Teaching Tuesday post of 2022! We have great cardiology content planned for this year. Mark your calendars 🗓️and follow along! #cardiotwitter

[Derick Gabel @derick_gabel]

Yes, don’t stop the statin! We are using more CV meds (SGLT2, GLP1, etc) now that could dilute this risk, but the US still has higher rates of CVD per capita than Denmark. High rates of mod statin use in this study also poses the Q if pts had suboptimal prevention to begin w/.

[Joel Peterson @joel_fetilide]

Colchicine’s potential toxicity is just not appreciated. Massive dose adjustments are required for seemingly innocuous combinations of meds

[Stephanie Dwyer Kaluzna @StephDwyer21]

Friendly reminder that MRAs are NOT potent anti-hypertensives in the setting of HFrEF. If K and renal fxn permit, hit ‘em with it.

https://t.co/Ihm7ndOmx3

@accpcardprn @jaccjournals #GDMTworks #CardioTwitter

[Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP,CACP @beaverspharmd]

This point can not be over stated. @ACCinTouch #ACCCVT @accpcardprn

[Justin Joy @HughHFrEFner]

A lottt of excitement in the #cardiotwitter and #TwitteRx world today...will have to wait and see

[Cait E. Kulig 🇺🇦 @Cait_Centra]

WAY too excited about the results announced today. #EMPEROR_PRESERVED found to ⬇️ 🫀death and HF hospitalizations in HFpEF patients. HFpEF, we are finally coming for you. 🎉🎉🎉 @accpcardprn https://t.co/hunscTuJV4

[Justin Joy @HughHFrEFner]

Smaller incremental benefits and ARR w/ newer therapies, even in the most ideal trial settings

seems like a recurring theme in current practice (a good thing!)

[Sean Stewart @umdpharmd]

@shestads @nationallipid A9. Exactly. A recent meta-analysis demonstrated LDL-C lowering was effective in reducing cardiovascular events in patients aged 75 years and older. https://t.co/iaQF4xaNdt
#NLATwitterChat #NLALipidRx